Bildkälla: Stockfoto

Swedencare: Continuing the triple-digit growth in Q3 - ABG

Q3 report due on 28 October
We expect sales & adj. EBIT of SEK 236m & SEK 56m
FY’21e EBIT down 5%, LT estimates more or less intact

Swedencare will report its Q3 results on October 28. We expect the company to post y-o-y growth of 239% (14% org, 226% M&A, -1% FX), reaching sales of SEK 236m. While the organic growth rates are coming down from the 45% in Q2 due to the reopening comparisons, we also suspect the company will continue to see struggles with its supply chain. As we recall from the company’s presentation on the ABGSC investor day, the company is experiencing problems with individual suppliers – an issue that should be resolved by the end of ’21 or beginning of ’22. In combination with mechanical M&A effects on the margin (acquired entities posting lower margins than group average), we expect the adj. EBIT margin to come in at 23.5% in Q3, -5pp y-o-y & -5pp q-o-q, resulting in adj. EBIT of SEK 56m.

On our updated estimates, the Swedencare share is trading at a ‘22e-‘23e EV/EBIT of 52x-42x. This corresponds to the share trading ~20% above the recently IPO’d Vimian, which has underperformed Swedencare during the last three months by almost 30pp.
Börsvärldens nyhetsbrev
ANNONSER